AMRX - Company ID 0001723128
The table below shows Amneal Pharmaceuticals, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$26.74M | $7.41M | -$4.41M | $139.71M | $120.34M | $148.13M |
| Capital expenditure | $8.18M | $13.16M | $9.20M | $9.69M | $10.79M | $11.78M |
| Investing cash flow | -$21.71M | -$17.80M | -$19.76M | -$11.74M | -$97.39M | -$12.69M |
| Dividends paid | - | - | - |
Amneal Pharmaceuticals, Inc. reported operating cash flow of $339.99M for fiscal year 2025. That is up 15.2% from $295.10M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from $115.06M (FY 2016) to $339.99M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$59.05M | -$39.17M | -$23.16M | -$12.90M | -$61.57M | -$26.15M |